Cargando…

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance

Detalles Bibliográficos
Autores principales:	Almandoz, Jaime P., Lingvay, Ildiko, Morales, Javier, Campos, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2020
Materias:	Practical Pointers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566932/ https://www.ncbi.nlm.nih.gov/pubmed/33132510 http://dx.doi.org/10.2337/cd19-0100

Ejemplares similares

El perro pointer
por: Taragano, R.
Publicado: (1977)

The continuing need for therapeutic agents for respiratory syncytial virus infection
por: Roberts, Norbert J
Publicado: (2023)

A Framework for Physician-Dentist Collaboration in Diabetes and Periodontitis
por: Elangovan, Satheesh, et al.
Publicado: (2014)

Ways Health Care Providers Can Promote Better Medication Adherence
por: Bussell, Jennifer K., et al.
Publicado: (2017)

A Safe and Simple Algorithm for Adding and Adjusting Mealtime Insulin to Basal-Only Therapy
por: Johnson, Mary L., et al.
Publicado: (2022)

Personalized Virtual Care Using Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Less Intensive Therapies
por: Reddy, Sushma, et al.
Publicado: (2023)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

El pointer
por: Fiorone, Fiorenzo
Publicado: (1993)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics
por: Lingvay, Ildiko, et al.
Publicado: (2023)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
por: Lorenz, Martin, et al.
Publicado: (2017)

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
por: Madsbad, Sten
Publicado: (2015)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
por: Choe, Hun Jee, et al.
Publicado: (2021)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
por: Baggio, Laurie L., et al.
Publicado: (2020)

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021)

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
por: Patel Chavez, Chandani, et al.
Publicado: (2021)

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
por: Lisco, Giuseppe, et al.
Publicado: (2023)

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
por: Unger, Jeffrey R., et al.
Publicado: (2011)

The Effect of Glucagon-Like Peptide-2 Receptor Agonists on Colonic Anastomotic Wound Healing
por: Redstone, Heather A., et al.
Publicado: (2010)

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
por: Hong, Yeonhee, et al.
Publicado: (2019)

Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
por: Veneti, Stavroula, et al.
Publicado: (2020)

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
por: Kalra, Sanjay, et al.
Publicado: (2021)

Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
por: Mouhammad, Zaynab Ahmad, et al.
Publicado: (2022)

Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
por: Song, Rui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_esh3fpbrof54ctd6ihstcbmrks